AUP Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc., (TSX-V:AUP) today announced that its President and Chief Executive Officer, Stephen Zaruby, will present a corporate overview of the company at the Jefferies 2014 Global Healthcare Conference, taking place June 2-5 in New York City.

Jefferies 2014 Global Healthcare Conference Aurinia Presentation Details

Date:	Tuesday, June 3, 2014
Time:	9:30am Eastern
Location:	Grand Hyatt Hotel, New York
Webcast:	http://wsw.com/webcast/jeff82/AUP.V

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia's current leadership team are former senior managers of Aspreva Pharmaceuticals ("Aspreva"), which Galenica acquired for C$915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study ("ALMS"), which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease. Aurinia holds global rights to all indications for voclosporin and has development and commercialization partners in Canada, Israel, South Africa and Greater China. In addition, Aurinia holds certain rights to exploit the ALMS database. More information is available at www.auriniapharma.com.

CONTACT: Company Contact:
         Stephen Zaruby
         President & CEO
         250-708-4293
         szaruby@auriniapharma.com
         
         or
         
         Michael R. Martin
         Chief Operating Officer
         250-708-4272